Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: Analysis of the RISING Study

Annals of the Rheumatic Diseases

Volumn 71, Issue 9, 2012, Pages 1583-1585

  Takeuchi, Tsutomu ^a   Miyasaka, Nobuyuki ^b   Tatsuki, Yoshihiko ^c   Yano, Toshiro ^c   Yoshinari, Toru ^c   Abe, Tohru ^d   Koike, Takao ^e  

^a KEIO UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

^e NTT CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; RHEUMATOID FACTOR; STROMELYSIN; TUMOR NECROSIS FACTOR;

ANTIBODY TITER; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; JOINT INJURY; LETTER; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHYSICAL CAPACITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION;

EID: 85027930906     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201069     Document Type: Letter

References (10)

1. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976-86.
2. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96. (Pubitemid 32368033)
3. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8. (Pubitemid 29352775)
4. Knudsen LS, Ostergaard M, Baslund B, et al. Plasma IL-6, plasma VEGF, and serum YKL-40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate. Scand J Rheumatol 2006;35:489-91. (Pubitemid 47215716)
5. Dain L, Braun-Moscovici Y, Baum E, et al. Modification of neutrophil function by plasma of rheumatoid arthritis patients treated with infliximab. Clin Exp Rheumatol 2006;24:38-44.
6. Takeuchi T, Miyasaka N, Inoue K, et al. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 2009;19:478-87.
7. Takeuchi T, Miyasaka N, Tatsuki Y, et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:1208-15.
8. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-9. (Pubitemid 34620190)
9. Rahman MU, Strusberg I, Geusens P, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66: 1233-8. (Pubitemid 47309743)
10. Inoue E, Yamanaka H, Hara M, et al. Comparison of Disease Activity Score (DAS) 28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 2007;66:407-9. (Pubitemid 46579645)